Tin tức & Cập nhật

The oral cytoskeleton disruptor sabizabulin shows antitumour activity in men with metastatic castration-resistant prostate cancer, while having a favourable safety profile, as shown in the results of a phase Ib/II trial.

Treatment with a novel combination of famitinib, camrelizumab, and nab-paclitaxel appears safe and effective in patients with advanced immunomodulatory triple-negative breast cancer (TNBC), as shown in the results of the phase II FUTURE-C-Plus trial.

A study conducted in England has shown that in patients with haematological malignancy, the risk of COVID-19–related mortality is greatly influenced by age.

Maintenance monotherapy with olaparib appears safe and effective in Asian patients with platinum-sensitive relapsed (PSR) ovarian cancer, regardless of their BRCA status, as shown in the results of the phase III, open-label, single-arm L-MOCA study.

In the ongoing phase III ATLAS study evaluating patients with newly diagnosed multiple myeloma (MM), progression-free survival (PFS) was better with maintenance treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) than lenalidomide (R) alone after autologous stem-cell transplantation (ASCT).

Long-term overall survival (OS) in patients with metastatic breast cancer (MBC) may be influenced by diabetes status, according to a retrospective study presented at ENDO 2022.

For individuals with obesity, undergoing weight-loss surgery may be a lifesaver, not only helping avert cancer-related deaths but also preventing the incidence of obesity-associated cancer, according to data from the SPLENDID (Surgical Procedures and Long-term Effectiveness in Neoplastic Disease Incidence and Death) study.

In men with metastatic prostate cancer, prior radical prostatectomy (RP) appears to reduce the risk of developing a castrate-resistant state, as compared with radiation therapy (RT), according to a recent study. Previous RP also seems to improve overall survival (OS).